Evandro Bezerra, MD, Mayo Clinic, Rochester, MN, comments on the barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL) who progress after CD19-directed CAR-T therapy. Approximately 60% of patients progress or relapse after treatment with CAR-T therapy and these patients have a very poor prognosis. A recent study showed that a significant proportion of these patients would be ineligible for clinical trials due to low blood counts and incomplete hematologic recovery. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.